Refractory Multiple Myeloma Clinical Trials

200 clinical trials for Refractory Multiple Myeloma across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment — RECRUITING · PHASE1
• SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE2
• Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma — RECRUITING · PHASE2
• Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma — RECRUITING · PHASE2
• Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma — RECRUITING · NA
• Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM — RECRUITING · PHASE1
• A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Elranatamab in R/R Multiple Myeloma — RECRUITING · PHASE2
• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease — RECRUITING · PHASE2
• Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM — RECRUITING · PHASE1
• BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma — RECRUITING · PHASE1
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers — RECRUITING · PHASE1
• Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab — RECRUITING · NA
• Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma — COMPLETED · PHASE2
• Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) — ACTIVE_NOT_RECRUITING · PHASE2
• Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib — ACTIVE_NOT_RECRUITING · PHASE2
• FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• TriPRIL CAR T Cells in Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Neurocognitive Trajectories After BCMA CAR-T — NOT_YET_RECRUITING
• Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE3
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) — ACTIVE_NOT_RECRUITING · PHASE2
• TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) — NOT_YET_RECRUITING · PHASE1
• CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• INfections in Patients Treated With CAR-T — NOT_YET_RECRUITING
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases — COMPLETED
• A Study of MCARH109 and MCARH125 in People With Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma — TERMINATED · NA
• A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan — ACTIVE_NOT_RECRUITING
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) — ACTIVE_NOT_RECRUITING · PHASE2
• CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma — SUSPENDED · PHASE1
• Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM — ACTIVE_NOT_RECRUITING · PHASE2
• MMRC Horizon One: RRMM (MMRC-099) — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search